Pharmagen, Inc.announced a private placement of 500,000 shares of series C convertible preferred stock at $1 per share for gross proceeds of $500,000 on December 12, 2013. The company will issue securities pursuant to exemption provided under Regulation D. On a fixed conversion, the holders of series C convertible preferred stock can acquire upon conversion, 15% of the then outstanding common shares of the company. On a variable conversion basis, the shares will be convertible at 33.33% of the lowest 5 closing bid prices of the common stock during the 10 days prior to the conversion. The shares will not be convertible in an event that the conversion will result in an ownership exceeding 9.99% by any single shareholder. The transaction will include participation from Richard A. Wolpow, Chairman and Interim Chief Operating Officer of the company for $100,000. Richard A. Wolpow will invest through Bagel Boy Equity Group II, LLC, an entity owned and controlled by him. The transaction was approved by the board of directors. Brian A. Lebrecht of Clyde Snow & Sessions, P.C. shall act as the legal advisor to the company.

On December 13, 2013, the company announced that it will issue 125,000 shares for gross proceeds of $125,000 with two accredited investors.

On February 14, 2014, the company announced that Richard A. Wolpow will subscribe for additional $100,000 in the transaction.

On March 19, 2014, the company announced that it has received $175,000 by issuance of 175,000 shares to three investors. David Rowley subscribed 25,000 shares of series C convertible preferred stock. As a part of the round David Rowley will join the company's board of directors. The company has received gross proceeds of $400,000 in the transaction.